Last reviewed · How we verify

NCT07062081

Correlation Between Acne Vulgaris and Lipid Profile Among Young Adults in Sohag Governorate

Not yet recruiting NA Last updated 14 July 2025
What this trial tests

NA trial testing lipid profile in Acne Vulgaris in 100 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
30 January 2026
30 January 2026

Quick facts

Lead sponsorSohag University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment100
Start date1 August 2025
Primary completion30 January 2026
Estimated completion30 January 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 12 to 45, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of lipid profile

Trials testing the same drug.

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07062081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing